Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821431 | 0.92 | ADORA1 (0.51) | ADORA1PTGDR2PDE4APDE4BPDE4C | |
| SCHEMBL6822087 | 0.90 | ADORA1 (0.43) | ADORA1PTGDR2PDE4APDE4BPDE4C | |
| SCHEMBL6822006 | 0.86 | ADORA1 (0.46) | ADORA1PTGDR2IGF1R | |
| SCHEMBL8810012 | 0.84 | ADORA1 (0.73) | ADORA1HSD17B10IGF1RHTT | |
| SCHEMBL6821421 | 0.82 | MAPK14 (0.42) | ADORA1PTGDR2HSD17B10 | |
| SCHEMBL6821959 | 0.82 | ADORA1 (0.42) | ADORA1PTGDR2IGF1R | |
| SCHEMBL6822330 | 0.82 | ADORA1 (0.41) | ADORA1PTGDR2HSD17B10IGF1R | |
| SCHEMBL6822329 | 0.80 | ADORA1 (0.41) | ADORA1PTGDR2PDE4APDE4BPDE4C | |
| SCHEMBL6822534 | 0.78 | FGFR1 (0.40) | ADORA1IGF1R | |
| SCHEMBL6822088 | 0.78 | ADORA1 (0.48) | ADORA1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885PTGDR2 216/4885PDE4A 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.